 |
|
|
| |
Elbasvir/Grazoprevir Plus Sofosbuvir ± Ribavirin in
Treatment-Naive And Treatment-Experienced People With Hepatitis C Virus Genotype 3 Infection and Compensated Cirrhosis: SVR24 Results of the C-ISLE Study
|
| |
| |
Reported by Jules Levin
EASL 2017
The International Liver
Congress™ 2017;
April 19-23, 2017;
Amsterdam, The Netherlands
Foster GR1; Agarwal K2; Cramp M3; Moreea S4; Barclay S5; Collier J6;
Brown AS7; Ryder SD8; Ustianowski A9; Forton DM10; Fox R11; Gordon F12;
Rosenberg WM13; Mutimer DJ14; Du J15; Gilbert CL15; Robertson MN15;
Barr E15; Haber B15
1The Royal London Hospital, London, UK; 2Institute of Liver Studies, Kings College Hospital, London, UK; 3South West Liver Unit, Derriford Hospital and Peninsula School of Medicine and Dentistry, Plymouth, UK; 4Bradford Teaching Hospitals Foundation Trust, Bradford, UK; 5Glasgow Royal Campus, Glasgow, UK; 6John Radcliffe Hospital, Oxford, UK; 7Imperial College Healthcare, London, UK; 8NIHR Biomedical Unit in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust and The University of Nottingham, Nottingham, UK; 9North Manchester General Hospital, Manchester, UK; 10St. Georges University of London, London, UK; 11Gartnavel General Hospital, Glasgow, UK; 12Hepatology Joint Clinical Research Unit, Bristol, UK; 13University College London, London, UK; 14QE Hospital, Birmingham, UK;
15Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
